Legend Biotech Corporation

With $834.6M in cash and $389.3M in debt, LEGN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$55.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -25.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $68.8M (2021) to $1.03B (2025), reflecting a 1395% increase over the period.

The relatively low beta of 0.30 suggests LEGN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, LEGN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing LEGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.